| (Values in U.S. Thousands) | Jun, 2025 | Jun, 2024 | Jun, 2023 | Jun, 2022 | Jun, 2021 |
| Sales | 30 | 120 | 110 | 90 | 70 |
| Sales Growth | -75.00% | +9.09% | +22.22% | +28.57% | +16.67% |
| Net Income | -162,790 | -220,240 | -142,520 | -92,820 | -45,340 |
| Net Income Growth | +26.09% | -54.53% | -53.54% | -104.72% | -308.47% |
Opthea Ltd ADR
(OPT)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Opthea Limited is a biotechnology company. It develops and commercializes therapies primarily for eye disease principally in Australia. Opthea Limited is based in South Yarra, Australia.